47 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
and development (R&D) expenses: R&D expenses were $49.9 million for the three months ended March 31, 2024, compared to $50.9 million for the same three months
6-K
EX-99.1
ALVO
Alvotech
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
revenues, costs from pre-commercial manufacturing activities were reported as R&D expenses.
Research and Development (R&D) Expenses: R&D expenses were
6-K
EX-99.1
ALVO
Alvotech
23 Feb 24
Current report (foreign)
8:39pm
biosimilar to Humira with IC status,” said Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva. "Biosimilars
6-K/A
EX-99.1
ALVO
Alvotech
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
to the recognition of cost of product revenues, costs from pre-commercial manufacturing activities were reported as R&D expenses.
Research … and development (R&D) expenses: R&D expenses were $152.8 million for the nine months ended September 30, 2023, compared to $133.1 million for the same nine
6-K
EX-99.1
zqc1dso
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am
6-K
EX-99.1
1alwmndn94
15 Nov 23
Alvotech Accepts Offer to Sell its Subsidiary in Hannover, Germany
7:30am
F-3
p1k26
20 Oct 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
5bj188x6 o3
3 Oct 23
Current report (foreign)
8:51am
6-K
EX-99.2
j71z l1xv1
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.8
soefu9
31 Aug 23
Current report (foreign)
8:00am
424B3
gpq1xjlu0qpm8r 9e1in
24 Jul 23
Prospectus supplement
8:03am
424B3
kxyebm nfb7166a2zh
24 Jul 23
Prospectus supplement
8:00am
F-3
lu6o82y8is4s9
14 Jul 23
Shelf registration (foreign)
4:56pm
POS AM
6u0a9mme
14 Jul 23
Prospectus update (post-effective amendment)
4:45pm
6-K
EX-99.1
3ms s5tlp
19 May 23
Alvotech Reports Financial Results for First three Months of 2023
11:54am
424B3
w5zoczo1
1 Dec 22
Prospectus supplement
5:27pm
424B3
rquko26z8k0lfkz
1 Dec 22
Prospectus supplement
5:25pm
6-K
EX-99.2
cuy2935n8mh3961
1 Dec 22
Alvotech submits its application for admission of the company’s shares to trading on Nasdaq Iceland Main Market
5:20pm
6-K
EX-99.1
z0v5rp8x v34
16 Nov 22
Alvotech Reports Financial Results for First Nine Months of 2022
6:19am